Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Alexion Pharmaceuticals, Inc.    ALXN   US0153511094

 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/10/2014 04/11/2014 04/14/2014 04/15/2014 04/16/2014 Date
144.19(c) 139.61(c) 141.97(c) 145.42(c) 149.05(c) Last
3 058 807 2 465 123 1 644 231 2 178 780 1 438 947 Volume
-7.49% -3.18% +1.69% +2.43% +2.50% Change
More quotes
Company
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, engages in the innovation, development, and commercialization of life-transforming therapeutic products for treating patients with severe and ultra-rare disorders. It focuses on developing products for the treatment of diseases in the... 
Surperformance© rating of Alexion Pharmaceuticals, I
Trading Rating : Investor Rating :
More about the company
Chart ALEXION PHARMACEUTICALS, I
Duration : Period :
Alexion Pharmaceuticals, I Technical Analysis Chart | ALXN | US0153511094 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 2 171 M
EBIT 2014 986 M
Net income 2014 736 M
Finance 2014 785 M
Yield 2014 -
Sales 2015 2 619 M
EBIT 2015 1 252 M
Net income 2015 903 M
Finance 2015 1 403 M
Yield 2015 -
PER 2014 40,94
PER 2015 32,11
EV / Sales 2014 12,6x
EV / Sales 2015 10,2x
Capitalization 28 086 M
More Financials
Latest news on ALEXION PHARMACEUTICALS, I
19h ago ALEXION PHARMACEUTICALS : Researchers to Showcase New Data on Asfotase Alfa in I..
2d ago ALEXION PHARMACEUTICALS : Acquisitions, Director Appointments, Collaborations, N..
5d ago ALEXION PHARMACEUTICALS : Researchers to Present New Data on Asfotase Alfa in In..
5d agoDJRiding the Tech Roller Coaster -2-
5d agoDJRiding the Tech Roller Coaster
6d ago S&P 500 MOVERS : Bbby, hpq
6d ago NASDAQ 100 MOVERS : Bbby, chrw
6d ago ALEXION PHARMACEUTICALS : to Report First Quarter 2014 Results on Thursday, Apri..
04/08 U.S. stock market may have stumbled, but signals still say 'go'
04/04 Momentum names may see more pain
03/29 Industry experts gather in London to capitalise on the $3.09bn lyophilisation..
03/28 As U.S. momentum stocks take beating, some sectors benefit
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Technical analysis
Income Statement Evolution
Alexion Pharmaceuticals, I : Income Statement Evolution
More Financials
EPS Revisions
Alexion Pharmaceuticals, I : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF